Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

v3.10.0.1
Revenue (Tables)
 6 Months Ended
Jun. 30, 2018
Revenue from Contract with Customer [Abstract]  
Revenue
During the three and six months ended June 30, 2018 and 2017, respectively, the Company recognized revenues as follows (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
License fees
$
11,224

 
$
1,507

 
$
14,668

 
$
2,516

Research and development services
467

 
346

 
1,084

 
680

Other revenues
—

 
—

 
91

 
—

Total Revenue
$
11,691

 
$
1,853

 
$
15,843

 
$
3,196


During the three and six months ended June 30, 2018 and 2017, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2018
 
2017
 
2018
 
2017
Seattle Genetics
$
2,425

 
$
—

 
$
2,731

 
$
—

AstraZeneca
6,390

 
592

 
8,937

 
592

Servier
1,419

 
363

 
2,627

 
689

Other
1,457

 
898

 
1,548

 
1,915

Total Revenue
$
11,691

 
$
1,853

 
$
15,843

 
$
3,196

Potential Milestone Payments
Under the Company´s existing strategic partnerships, Pieris could receive the following potential milestone payments (in millions):
 
Research, Development & Commercial Milestones
 
Sales Milestones
Seattle Genetics
$
769

 
$
450

AstraZeneca
1,111

 
960

Servier
1,013

 
917

Total potential milestone payments
$
2,893

 
$
2,327